These tumor‐resident CD8+ TIL have been shown to remain anchored at sites of tumorigenesis where they provide rapid local protection19, 20 and have been associated with improved survival of patients with a range of solid cancers.21 The gene discussed is CD8A; the disease is neoplasm.